Wound dressing for use in vacuum therapy

Information

  • Patent Grant
  • 10968543
  • Patent Number
    10,968,543
  • Date Filed
    Thursday, November 29, 2012
    11 years ago
  • Date Issued
    Tuesday, April 6, 2021
    3 years ago
Abstract
A wound dressing for use in vacuum wound therapy comprising a wound contact layer which is an open structure comprising a yarn comprising gel-forming filaments or fibres, the structure having a porosity which allows exudate to flow through it.
Description
CROSS-REFERENCE

This application is a U.S. National Stage of PCT/GB2012/052950, filed Nov. 29, 2012; which claims the benefit of priority of GB1120693.5; filed Dec. 1, 2011; each of which is incorporated herein be reference in their entirety.


The present invention relates to a device and kit for treating a wound with a dressing and vacuum.


Vacuum has been used to increase blood flow to wound tissue and to remove exudate from the wound site. In general vacuum treatment uses a device comprising a cover for sealing about the outer perimeter of the wound, under which a vacuum is established to act on the wound surface. The vacuum applied to the wound surface accelerates healing of chronic wounds. A screen of open cell foam material or gauze is typically used under the cover to provide the space in which the vacuum is formed and to reduce tissue ingrowth. Sufficient vacuum is applied for a suitable duration to promote tissue migration in order to facilitate the closure of the wound. Suitable vacuum is between about 0.1 and 0.99 atmospheres. The vacuum can be substantially continuous or can be cyclic with the application of vacuum for alternating periods of application and nonapplication.


Many common conventional and advanced wound contact dressings have shortcomings particularly for use in suction wound therapy. In an example, gauze and other similar flat fabric materials are commonly used as wound dressings. When gauze is in contact with a wound it becomes wet with exudate and collapses into the wound. New tissue growth can engulf the gauze making it difficult and painful to remove from the wound. When foam is in contact with a wound and vacuum is applied, the foam can collapse and in-growth of tissue can occur into the collapsed cell structure of the foam. In order to overcome this problem relatively rigid perforated sheets have been used to contact the wound. However, they are not sufficiently flexible and conformable to comfortably and adequately conform to wound surfaces that are often irregular in contour. A dressing having such an inflexible or rigid structured material or wound contact layer can cause unnecessary pain and discomfort to a patient.


In WO 2006/052839 a vacuum wound dressing is described which is a fibrous blend or fibrous material that forms a cohesive gel when wetted with wound exudate. The dressing is in the form of a non-woven fibrous mat.


A wound dressing for use in vacuum wound therapy preferably has some or all of the following characteristics and properties:

    • it is porous to allow exudate to flow;
    • it has pores or holes to enable the underlying tissue to feel the effects of tissue strain;
    • it can be easily folded or scrunched to fill the wound site;
    • if fibrous, it has minimal fibre loss into the wound;
    • it presents the same material properties to the side of the wound as it does to the wound bed so that the wound contact surface is consistent over the whole wound;
    • it resists tissue ingrowth;
    • it has sufficient wet strength to facilitate easy removal;
    • it does not exert pressure on the wound bed on absorption of exudate;
    • it is suitable for a range of sizes of wound and for various shapes and depths;
    • it has minimal bioadhesion to minimise disruption to the wound bed on removal;
    • it imposes beneficial strain on the tissue when suction is applied to it.


We have found that it is possible to provide a gel-forming wound dressing with many of the above desirable properties and which overcomes some of the problems of tissue ingrowth identified above while filling the wound and allowing exudate to flow out of the wound site when a vacuum is applied.


Accordingly the invention provides a wound dressing for use in vacuum wound therapy comprising a wound contact layer which is an open structure comprising a yarn which comprises gel-forming filaments or fibres, the structure having a porosity which allows exudate to flow through it.


It has been found that strain imposed on the tissue by the vacuum is believed to stimulate new tissue growth and assist healing. The porosity present in the open structure of the dressing according to the invention is believed to facilitate the application of strain to the tissue of the wound.


The open structure can be in the form of a net knitted, woven or embroidered from a yarn comprising gel-forming filaments or fibres. By the term yarn is meant a thread or strand of continuous filament or staple fibres. Alternatively the open structure can be first knitted, woven or embroidered from a textile yarn which is then chemically modified to impart gel-forming properties to it. For instance, the yarn can be a cellulose yarn which is knitted or woven to form the open structure and is then chemically modified to give the fibres greater absorbency and gelling properties.


By gel forming fibres is meant hygroscopic fibres which upon the uptake of wound exudate become moist slippery or gelatinous and thus reduce the tendency for the surrounding fibres to adhere to the wound. The gel forming fibres can be of the type which retain their structural integrity on absorbtion of exudate or can be of the type which lose their fibrous form and become a structureless gel. The gel forming fibres are preferably spun sodium carboxymethylcellulose fibres, chemically modified cellulosic fibres, pectin fibres, alginate fibres, chitosan fibres, hyaluronic acid fibres, or other polysaccharide fibres or fibres derived from gums. The cellulosic fibres preferably have a degree of substitution of at least 0.05 substituted groups per glucose unit. The gel forming fibres preferably have an absorbency of at least 2 grams 0.9% saline solution per gram of fibre (as measured by the free swell absorbency method BS EN 13726-1:2002 Test methods for primary wound dressings—Part 1: Aspects of absorbency, Method 3.2 free swell absorptive capacity).


Preferably the gel forming fibres have an absorbency of at least 10 g/g as measured in the free swell absorbency method, more preferably between 15 g/g and 25 g/g.


The dressing may for instance comprise non gel forming fibres and in particular textile fibres such as Tencel, cotton or viscose and may comprise lycra or other elastic fibre. Preferably the textile fibres have an absorbency of less than 10 g/g as measured by the free swell method and more preferably less than 5 g/g.


The pore size of the dressing in part determines the strain placed on the wound when suction is applied. The strain is also determined by the uniformity of the dressing over the area treated. The maximum strain and the uniformity of its application will therefore depend not only on the pore sixe of the open structure but also on the linear density of the yarn used to make the dressing. Maximum strain can be achieved by increasing the pore size or increasing the yarn linear density. Uniformity is increased by decreasing the pore size and decreasing the yarn linear density. We have found that acceptable strain is placed on the wound where the structure preferably has a pore size of between 0.5 mm2 to 5.0 mm2, more preferably between 3.0 mm2 to 4.0 mm2 and the yarn has a linear density of 20 tex to 40 tex.


The open structure can be in the form of a net with yarn joined at intervals to form a set of meshes or the open structure can be knitted with a pore sizes as mentioned above.


An advantage of such an open structure is that it is easily folded or crumpled to fit the wound and pack the wound site. Due to the structure, the dressing still allows exudate to pass through it when a vacuum is applied to the wound even though the dressing may not be co-planar with the wound bed. The conformability of the open structure allows all parts of the wound to be contacted with a similar dressing structure so that for instance the sides of the wound are contacted by the open structure as well as the wound bed.


In a further embodiment the invention provides a device for vacuum wound therapy comprising a wound dressing which is an open structure comprising a yarn of gel-forming filaments or fibres, the structure having a porosity which allows exudate to flow through it;

    • a source of vacuum situated to be separated from the wound bed by the wound dressing; and
    • a vacuum sealing layer covering the wound dressing and adapted to retain relative vacuum in the wound contact layer.


The open structure of the dressing of the invention can be made by first forming a yarn of gelling fibres. This may be done in various ways. For example gel forming fibres, which are for instance any of those mentioned above or can be modified cellulose, or carboxymethyl cellulose or alginate, can be spun into yarns comprising various blends of gel-forming staple fibres and textile fibres. The spinning may be done by first carding the fibres in the blend and spinning a yarn from the carded blend.


We have found that particularly suitable yarns can be formed by rotor spinning or open end spinning. In such a process, staple gel-forming fibres are blended with textile fibres and carded to produce a continuous web. The web is condensed to produce a card sliver and then rotor spun. In rotor spinning, a high speed centrifuge is used to collect and twist individual fibres into a yarn. The yarns produced from this technique have the characteristics of sufficient tensile strength to enable them to be further processed using knitting or weaving machinery.


A further embodiment of the invention provides a process for making a yarn comprising gel-forming fibres comprising the steps of:

    • blending staple gel-forming fibres optionally with textile fibres;
    • carding to form a continuous web;
    • drawing the web to produce a sliver and rotor spinning to produce a yarn.


Yarns produced by this method preferably comprise from 30% to 100% by weight gel-forming fibres and 0% to 70% by weight textile fibres. More preferably the yarns comprise from 50% to 100% by weight of gel-forming fibres with the balance of textile fibres and most preferably from 60% to 100% by weight of gel-forming fibres.


The fibres present in the spun yarn preferably have a staple length of 30 to 60 mm, more preferably 40 to 55 mm and most preferably 45 to 55 mm.


A yarn made according to the processes of the present invention need not contain textile fibres enabling structures to be produced which consist wholly of gel-forming fibres.


A gelling yarn can be produced using a spun yarn consisting of natural cellulose fibres or solvent spun cellulose staple fibres or a blend of cellulose fibres and other textile fibres or by using a filament yarn of solvent spun cellulose which is then converted to chemically modify the yarn to produce gelling properties. For example, Lyocell yarns can be used as a starting material and converted in a kier process to impart gel-forming behaviour to the yarn.


Yarns made according to the processes of the present invention preferably have a dry tensile strength of at least 10 cN/tex, preferably from 10 to 40 cN/tex and most preferably from 16 to 35 cN/tex as measured by British Standard ISO 2062 2009.


Alternatively the open structure of the dressing of the invention can be made by weaving using a textile yarn and the resulting fabric then converted to impart gel-forming behaviour to it to form an open structure of gel-forming fibres.


It is also possible to warp or weft knit an open structure using a textile yarn such as Lyocell and then convert the resulting fabric to make the wound dressing of the invention. Further it is possible to embroider an open structure in textile yarn onto a support film which is then removed for instance by washing and the resulting structure converted to form an open structure comprising a yarn of gel-forming fibres.


In a further aspect the invention provides a process for making an open structure or net of gel-forming fibres by:

    • embroidering an open structure in a textile yarn on a soluble support film;
    • removing the support film by dissolving it and converting the structure give gel forming characteristics to the yarn and to form a structure comprising a yarn of gel forming fibres.


A preferred method of converting the yarns or fabrics is described in WO 00/01425. For example the yarns or fabrics can be carboxymethylated by pumping a reaction fluid through the reaction vessel and therefore the cellulosic materials at 65° C. for 90 minutes. The reaction fluid is a solution of an alkali (typically sodium hydroxide) and sodium monochloroacetate in industrial denatured alcohol. After the reaction time, the reaction is neutralised with acid and washed before being dried in a laboratory oven for 1 hour at 40° C.





Preferred embodiments of the invention are illustrated in the drawings in which:



FIG. 1 is a graph showing tensile strengths for yarns according to the invention;



FIG. 2 shows open structures produced from a yarn comprising gel forming fibres in a relaxed, slightly stretched out and wet and slightly stretched out state;



FIG. 3a shows a fabric knitted using Tencel warps and weft insertion of a yarn according to the invention in both dray and wet states;



FIG. 3b shows the locking in of one yarn by another for the fabrics in FIG. 3a;



FIG. 4 shows an open structure produced by embroidering a textile yarn on a film, (a) showing the embroidered two layered structure on a film, (b) showing the converted dry structure and (c) showing that structure wet;



FIG. 5 shows a locked in a warp knitted structure produced using HF-2011/250;



FIG. 6 shows a microscope image of FIG. 5 showing connecting yarns forming stitches within the pillar stitch;



FIG. 7 shows a converted woven structure in a dry state;



FIG. 8 shows the structure from FIG. 7 but wet.





The invention is illustrated by the following examples.


EXAMPLE 1

Spinning Yarn from Staple Gel-Forming Fibres


Lyocell fibres and carboxymethyl cellulose staple fibres in blends of 50:50, 60:40 and 70:30 CMC:Lyocell were made by carding on a Trutzschler cotton card and spinning the resulting sliver at a twist of 650 turns/meter.


EXAMPLE 2

Converting a Textile Yarn to a Gel-Forming Yarn


Yarns were converted in the laboratory using a mini kier. In both trials, staple and filament lyocell yarns were converted. The yarns used for the conversion were staple 33 Tex Tencel®; HF-2011/090; and 20 Tex filament lyocell batches HF-2011/051 (trial 1) and HF-2011/125 (trial 2). Tencel® is a Lenzing owned, trademarked brand of lyocell and the Tencel® yarn used was a spun staple yarn. The filament lyocell was supplied by Acelon chemicals and Fiber Corporation (Taiwan) via Offtree Ltd.


The advantages of converting a yarn are that complete cones of yarn could potentially be converted in one relatively simple process, and the processing of gelling fibres is avoided, thus reducing the number of processing steps required and damage to the fibres.


Trial 1—Yarn Wrapped Around Kier Core


In this trial, Tencel® yarn was tightly wrapped around the perforated core of the kier using an electric drill to rotate the core and pull the yarn from the packages for speed. This meant that the yarn was wrapped tightly around the core under tension.


The yarn was converted by a process as described in WO 00/01425 in which carboxymethylation was carried out by pumping fluid through the kier and therefore the cellulosic materials at 65 C. for 90 minutes. The reaction fluid was a solution of an alkali (typically sodium hydroxide) and sodium monochloroacetate in industrial denatured alcohol. After the reaction time, the reaction was neutralised with acid and washed before being dried in a laboratory oven for 1 hour at 40 C.


The conversion was successful and both staple and filament gelling yarns were produced; HF-2011/103 and HF-2011/105 respectively. Due to the tight and uneven wrapping of the staple yarn around the core, it had to be removed using a scalpel which left multiple short lengths (approximately 14 cm) of the converted yarn.


Trial 2—Small Yarn Hanks


The aim of the second trial was to produce longer lengths of converted yarns for testing hence a small hank was made of each the staple and filament lyocell yarns by hand and these were placed between layers of fabric for the conversion.


The yarn was converted by placing the hanks in a kier and converting to form a gel-forming fibre yarn as described above for Trial 1.


The conversion was successful and both staple and filament gelling yarns were produced; HF-2011/146 and HF-2011/147 respectively.


Yarn Summary
















Sample
HF#


















Gelling Yarns
50:50 Spun staple gelling yarn
HF-2011/001



60:40 Spun staple gelling yarn
HF-2011/088



70:30 Spun staple gelling yarn
HF-2011/108



Converted staple yarn (trial 1)
HF-2011/103



Converted filament yarn (trial 1)
HF-2011/105



Converted staple yarn (trial 2)
HF-2011/146



Converted filament yarn (trial 2)
HF-2011/147


Non-Gelling Yarns
Staple Tencel ®
HF-2011/090



Filament lyocell (sample)
HF-2011/051



Filament lyocell (bulk)
HF-2011/125










Results from Examples 1 and 2


With the exception of HF-2011/051, all of the yarns were tested for wet and dry tensile strength. Adaptations were made to the standard method BS EN ISO 2062:2009; “Textiles—Yarns from packages: Determination of single-end breaking force and elongation at break using constant rate of extension (CRE) tester”. A Zwick tensile testing machine was used with a gauge length of 100 mm. The test uses a 100N or 20N liad cell to exert a constant rate of extension on the yarn until the breaking point is reached. Wet tensile testing was measured by wetting the samples with 0.2 ml of solution A in the central 3 to 4 cm of each yarn and leaving for 1 minute. The wetted sample was then placed in the jaws of the Zwick and clamped shut. Tensile strength was tested as the yarns produced need to be strong enough to withstand the tensions and forces applied during knitting, weaving and embroidery.


Tensile Strength


The results showed that all of the yarns were stronger when they were dry than when they were wet, with HF-2011/108, the 70:30 gelling yarn, showing the largest proportional strength decrease.


Of the yarns tested, HF-2011/108 was the weakest yarn both when wet and dry with tensile strengths of 12.4 and 3.4 cN/Tex respectively, despite containing 30% lyocell fibres. As this was the weakest yarn, but it was successfully weft knitted; HF-2011/120 and woven; HF-2011/169 into fabrics, it is believed that all of the other yarns would also be strong enough to be converted into fabrics.


Both approaches successfully produced gelling yarns.


EXAMPLE 3

Producing Open Structures from Gel-Forming Yarn


A yarn was produced with a 2/12 s worsted count consisting of 60% CMC fibres and 40% viscose fibres, each with a staple length of ˜40 mm and the fibres were blended at the fibre stage. The yarn was produced using a worsted system and two 12 count strands were plied together. When dry, the yarn felt soft and the plying was clear as the two strands wrapped around each other. On wetting with Solution A, the yarn gelled and swelled to form a thicker yarn, and the plying became more pronounced.


A sample was made using this yarn on a warp knitting/stitch bonding machine and was hydrated with Solution A.


The sample structure was knitted with Tencel warp yarns and gelling yarn wefts in a net-like arrangement, which is especially visible when the structure is opened by gentle stretching, as shown in FIG. 2. On wetting the structure gels slightly and feels wet but it holds its open shape well.


EXAMPLE 4

A yarn comprising gel forming fibres was produced by the method of example 3. Using this yarn a fabric was knitted using Tencel warps and gelling yarn weft insertion. The weft yarns were inserted in such a way that they became locked in due to the pattern of knitting. This material has the weft yarn path notation of 0-1/1-1/1-2/2-3/3-2/2-1/1-2//. The material felt quite thin and when wet, it gels but seems to hold fluid on its surface.


EXAMPLE 5

Producing Open Structures from a Textile Yarn


Using a Tajima TMEX-C1201 embroidery machine fabrics were produced on a PVA film from lyocell thread (on the bobbin and as the top thread).

  • Thread=Gütermann 120 Tex lyocell thread from Tony Slade (T.S. Sewing Supplies)
  • Software=Wilcom ES
  • Programme name=honeycomb
  • Number of stitches=12,369 per 2 layers
  • Backing film=Soluble PVA film
  • Speed used=1200 rpm


The film was removed by washing in warm tap water in a sink using lots of agitation until the film looked to have been removed. The samples were air dried on the bench The fabrics were converted by a process as described in WO 00/01425 and detailed in Example 2.


EXAMPLE 6

Warp Knitting to Produce a Locked in Structure.


To produce a fully locked in structure, a warp knitted fabric without any weft inlays is preferred. In the following example (FIG. 5) a fabric has been formed from a set of 4 pillar stitches, the yarn then underlaps to the adjacent set of pillar stitches and continues to form pillar stitches on this needle before underlapping back to the initial needle. Eg a typical yarn path notation for the simplest type of this fabric would be 0-2/2-1/2-1/2-0/0-1/0-1//. By using 2 sets of warp ends within one set of chain stitch alternating the yarn used for each stitch stops the structure being able to be unravelled easily. This structure could be complicated by using more needles within the design or using addition warp beams to underlap in opposite directions. The fabric produced is a locked in structure as the each knitted stitch is secured by a knitted stitch of another yarn end stopping the structure from unravelling and the threads going perpendicular to the pillar stitches also form loops within the structure, as shown in FIG. 6, ensuring that these are locked in.


EXAMPLE 7

Weaving


Open plain weave structures have been produced on a Northrop loom, using a gelling yarn previously described, HF-2011/108 to produce fabric HF-2011/169. And by using a Tencel spun yarn HF-2011/090 and converting at the fabric stage, to produce fabric HF-2011/136. The structure uses a warp density of 7.8 ends/cm and a weft density of 5.5 picks/cm.



FIG. 7 shows HF-2011/136, the sample converted at the fabric stage using the lab conversion process as previously described. This produced an open structure that is thin and flexible in its dry form. When wet this structure is less stable and bunches, but forms a gelled structure as shown in FIG. 8.


EXAMPLE 8

To produce a locked in woven sample, leno weaving is used. Leno weaving is a form of weaving in which warp threads are made to cross one another between the picks. As the warp yarns cross one another they are able to hold the weft yarns in place so little movement occurs within the structure. When the sample is cut theoretically the yarns should not be able to be removed as the free end is held in place by multiple warps within the rest of the structure. The leno can be applied to all or some of the yarns within the fabric.

Claims
  • 1. A wound dressing for use in vacuum wound therapy comprising a wound contact layer comprising an open structure in a form of a net comprising a spun yarn comprising a blend of gel-forming filaments or fibres and textile fibres, the net having a pore or mesh size from 0.5 mm2 to 5.0 mm2 that allows exudate to flow through the net, wherein the yarn has a linear density of 20 tex to 40 tex, wherein the yarn has a dry tensile strength of at least 10 cN/tex, wherein the textile fibers have an absorbency of between 5 g/g and 10 g/g as measured by the free swell method, and wherein the blend of gel-forming filaments or fibres and textile fibres includes only one type of gel-forming filaments or fibres.
  • 2. A wound dressing as claimed in claim 1 wherein the net is knitted, woven, or embroidered.
  • 3. A wound dressing as claimed in claim 1 wherein the pore or mesh size of the net is between 3.0 mm2 to 4.0 mm2.
  • 4. A wound dressing as claimed in claim 1 wherein the net is knitted.
  • 5. A wound dressing as claimed in claim 1 wherein the net is joined at intervals to form a set of meshes.
  • 6. A wound dressing as claimed in claim 1 wherein the yarn comprises 30% to 100% by weight gel-forming filaments or fibres.
  • 7. A wound dressing as claimed in claim 1 wherein the net comprises 50% to 100% by weight gel-forming filaments or fibres.
  • 8. The wound dressing of claim 1 wherein the yarn has a dry tensile strength from 10 cN/tex to 40 cN/tex.
  • 9. The wound dressing of claim 1 wherein the spun yarn comprises a blend of the gel-forming filaments or fibres and the textile fibres in a ratio of 60:40 to 70:30.
  • 10. The wound dressing of claim 1, wherein the pore or mesh size of the net facilitates application of strain to tissue through pores or mesh of the net to stimulate tissue growth when a vacuum of at least 0.4 atm is applied by a vacuum source to the wound dressing such that a relative vacuum is retained in the wound dressing.
  • 11. A device for vacuum wound therapy comprising: a wound dressing comprising an open structure in a form of a net comprising a spun yarn comprising a blend of gel-forming filaments or fibres and textile fibres, the net having a pore or mesh size from 0.5 mm2 to 5.0 mm2 that allows exudate to flow through the net, wherein the yarn has a linear density of 20 tex to 40 tex, wherein the yarn has a dry tensile strength of at least 10 cN/tex, and wherein the blend of gel-forming filaments or fibres and textile fibres includes only one type of gel-forming filaments or fibres;a source of vacuum situated to be separated from a wound bed by the wound dressing; anda vacuum sealing layer separate from the wound dressing that covers the wound dressing and is adapted to retain relative vacuum in the wound dressing,wherein the pore or mesh size of the net facilitates application of strain to tissue through pores or mesh of the net to stimulate tissue growth when a vacuum of at least 0.4 atm is applied by the source of vacuum to the wound dressing such that the relative vacuum is retained in the wound dressing by the vacuum sealing layer.
  • 12. A device as claimed in claim 11 wherein the net is knitted, woven, or embroidered.
  • 13. A device as claimed in claim 11 wherein the yarn comprises 30% to 100% by weight gel-forming filaments or fibres.
  • 14. A device as claimed in claim 11 wherein the net comprises 50% to 100% by weight gel-forming filaments or fibres.
  • 15. The device of claim 11 wherein the yarn has a dry tensile strength from 10 cN/tex to 40 cN/tex.
  • 16. The device of claim 11 wherein the spun yarn comprises a blend of the gel-forming filaments or fibres and the textile fibres in a ratio of 60:40 to 70:30.
  • 17. The device of claim 11, wherein the textile fibers have an absorbency of between 5 g/g and 10 g/g as measured by the free swell method.
  • 18. A wound dressing comprising a wound contact layer comprising an open structure in a form of a net comprising a spun yarn comprising a blend of gel-forming filaments or fibres and textile fibres, the net having a pore or mesh size from 0.5 mm2 to 5.0 mm2 that allows exudate to flow through the net, wherein the yarn has a linear density of 20 tex to 40 tex, wherein the yarn has a dry tensile strength of at least 10 cN/tex, and wherein the blend of gel-forming filaments or fibres and textile fibres includes only one type of gel-forming filaments or fibres.
  • 19. The wound dressing of claim 18 wherein the yarn has a dry tensile strength from 10 cN/tex to 40 cN/tex.
  • 20. The wound dressing of claim 18, wherein the pore or mesh size of the net facilitates application of strain to tissue through pores or mesh of the net to stimulate tissue growth when a vacuum of at least 0.4 atm is applied by a vacuum source to the wound dressing such that a relative vacuum is retained in the wound dressing.
Priority Claims (1)
Number Date Country Kind
1120693 Dec 2011 GB national
PCT Information
Filing Document Filing Date Country Kind
PCT/GB2012/052950 11/29/2012 WO 00
Publishing Document Publishing Date Country Kind
WO2013/079947 6/6/2013 WO A
US Referenced Citations (256)
Number Name Date Kind
4984570 Langen Jan 1991 A
5731083 Bahia et al. Mar 1998 A
6268544 Court Jul 2001 B1
6458460 Griffiths et al. Oct 2002 B1
6471982 Lydon et al. Oct 2002 B1
6548730 Patel et al. Apr 2003 B1
6656496 Kilpadi Dec 2003 B1
7951124 Boehringer et al. May 2011 B2
10016537 Menon et al. Jul 2018 B2
10046096 Askem et al. Aug 2018 B2
10076447 Barta et al. Sep 2018 B2
10143784 Walton et al. Dec 2018 B2
10426670 von Blucher et al. Oct 2019 B2
10426747 Johnson Oct 2019 B2
10426875 Blott et al. Oct 2019 B2
10434015 Taylor et al. Oct 2019 B2
10434142 Niazi et al. Oct 2019 B2
10434210 Olson et al. Oct 2019 B2
10434284 Hanson et al. Oct 2019 B2
D866756 Allen et al. Nov 2019 S
10463773 Haggstrom et al. Nov 2019 B2
10470933 Riesinger Nov 2019 B2
10470936 Wohlgemuth et al. Nov 2019 B2
10473345 Barta et al. Nov 2019 B2
10485707 Sexton Nov 2019 B2
10485906 Freedman et al. Nov 2019 B2
10492956 Zamierowski Dec 2019 B2
10493184 Collinson et al. Dec 2019 B2
10493185 Stokes et al. Dec 2019 B2
10500103 Crolzat et al. Dec 2019 B2
10500173 Yang et al. Dec 2019 B2
10500301 Laurensou Dec 2019 B2
10500302 Holm et al. Dec 2019 B2
10506928 Locke et al. Dec 2019 B2
10507141 Allen et al. Dec 2019 B2
10532137 Pratt et al. Jan 2020 B2
10532194 Locke et al. Jan 2020 B2
10537657 Phillips et al. Jan 2020 B2
10542936 Goldberg et al. Jan 2020 B2
10543133 Shaw et al. Jan 2020 B2
10543293 Suschek Jan 2020 B2
10555838 Wu et al. Feb 2020 B2
10555839 Hartwell Feb 2020 B2
10556044 Robinson et al. Feb 2020 B2
10561536 Holm et al. Feb 2020 B2
10568767 Addison et al. Feb 2020 B2
10568768 Long et al. Feb 2020 B2
10568771 MacDonald et al. Feb 2020 B2
10576037 Harrell Mar 2020 B2
10576189 Locke et al. Mar 2020 B2
10589007 Coulthard et al. Mar 2020 B2
10610415 Griffey et al. Apr 2020 B2
10610623 Robinson et al. Apr 2020 B2
10618266 Wright et al. Apr 2020 B2
10624984 Courage et al. Apr 2020 B2
10625002 Locke et al. Apr 2020 B2
10632019 Vitaris Apr 2020 B2
10632224 Hardy et al. Apr 2020 B2
10639206 Hu et al. May 2020 B2
10639404 Lichtenstein May 2020 B2
10653562 Robinson et al. May 2020 B2
10653810 Datt et al. May 2020 B2
10653823 Bharti et al. May 2020 B2
10660799 Wu et al. May 2020 B2
10660992 Canner et al. May 2020 B2
10660994 Askem et al. May 2020 B2
10667955 Allen et al. Jun 2020 B2
10667956 Van Holten et al. Jun 2020 B2
10682258 Manwaring et al. Jun 2020 B2
10682259 Hunt et al. Jun 2020 B2
10682318 Twomey et al. Jun 2020 B2
10682386 Ellis-Behnke et al. Jun 2020 B2
10687983 Dahlberg et al. Jun 2020 B2
10687985 Lee et al. Jun 2020 B2
10688215 Munro et al. Jun 2020 B2
10688217 Hanson et al. Jun 2020 B2
10744040 Kazala, Jr. et al. Jun 2020 B2
RE48117 Albert et al. Jul 2020 E
10702419 Locke et al. Jul 2020 B2
10702420 Hammond et al. Jul 2020 B2
10703942 Tunius Jul 2020 B2
10709760 Gronberg et al. Jul 2020 B2
10709883 Spector Jul 2020 B2
10716711 Locke et al. Jul 2020 B2
10716874 Koyama et al. Jul 2020 B2
10729590 Simmons et al. Aug 2020 B2
10736787 Hannigan et al. Aug 2020 B2
10736788 Locke et al. Aug 2020 B2
10736985 Odermatt et al. Aug 2020 B2
10743900 Ingram et al. Aug 2020 B2
10744041 Hartwell Aug 2020 B2
10744237 Guidi et al. Aug 2020 B2
10744238 Guidi et al. Aug 2020 B2
10744240 Simmons et al. Aug 2020 B2
10751442 Bonnefin et al. Aug 2020 B2
10751452 Topaz Aug 2020 B2
10758423 Pigg et al. Sep 2020 B2
10758424 Blott et al. Sep 2020 B2
10758425 Blott et al. Sep 2020 B2
10758426 Eddy Sep 2020 B2
10758651 Blott et al. Sep 2020 B2
10765561 Lattimore et al. Sep 2020 B2
10765783 Locke et al. Sep 2020 B2
10772767 Bjork et al. Sep 2020 B2
10780203 Coulthard et al. Sep 2020 B2
10792191 Robinson et al. Oct 2020 B2
10792192 Tout et al. Oct 2020 B2
10792337 Leung et al. Oct 2020 B2
10792404 Hu et al. Oct 2020 B2
10792482 Randolph et al. Oct 2020 B2
20020129596 Driggars Sep 2002 A1
20060155260 Blott et al. Jul 2006 A1
20060172000 Cullen et al. Aug 2006 A1
20070066945 Martin et al. Mar 2007 A1
20070185426 Ambrosio et al. Aug 2007 A1
20070219512 Heaton et al. Sep 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070239078 Jaeb Oct 2007 A1
20090234307 Vitaris Sep 2009 A1
20090259203 Hu et al. Oct 2009 A1
20090293887 Wilkes et al. Dec 2009 A1
20090299303 Seegert Dec 2009 A1
20100015208 Kershaw et al. Jan 2010 A1
20100030178 MacMeccan et al. Feb 2010 A1
20100042034 Riesinger Feb 2010 A1
20100125233 Edward et al. May 2010 A1
20100125258 Coulthard et al. May 2010 A1
20100137775 Hu et al. Jun 2010 A1
20100185163 Heagle Jul 2010 A1
20100298790 Guidi et al. Nov 2010 A1
20110015595 Robinson et al. Jan 2011 A1
20110028918 Hartwell Feb 2011 A1
20110112457 Holm et al. May 2011 A1
20110178451 Robinson et al. Jul 2011 A1
20110213319 Blott Sep 2011 A1
20110224593 Tunius Sep 2011 A1
20110224630 Simmons et al. Sep 2011 A1
20110230849 Coulthard et al. Sep 2011 A1
20110251566 Zimnitsky et al. Oct 2011 A1
20110257572 Locke et al. Oct 2011 A1
20110257573 Hong et al. Oct 2011 A1
20110275972 Rosenberg Nov 2011 A1
20110282309 Adie et al. Nov 2011 A1
20120071845 Hu et al. Mar 2012 A1
20120130332 Cotton et al. May 2012 A1
20120136325 Allen et al. May 2012 A1
20120209226 Simmons et al. Aug 2012 A1
20120276183 Bradford Nov 2012 A1
20130053795 Coulthard et al. Feb 2013 A1
20130123728 Pratt et al. May 2013 A1
20130226063 Taylor et al. Aug 2013 A1
20140005618 Locke et al. Jan 2014 A1
20140074053 Locke et al. Mar 2014 A1
20140188060 Robinson et al. Jul 2014 A1
20140194838 Wibaux et al. Jul 2014 A1
20140200532 Robinson et al. Jul 2014 A1
20140236112 Von Wolff et al. Aug 2014 A1
20140256925 Catchmark et al. Sep 2014 A1
20140276499 Locke et al. Sep 2014 A1
20140296804 Hicks et al. Oct 2014 A1
20140308338 Nierle et al. Oct 2014 A1
20140309574 Cotton Oct 2014 A1
20140323999 Bonnefin et al. Oct 2014 A1
20150018433 Leipzig et al. Jan 2015 A1
20150057624 Simmons et al. Feb 2015 A1
20150071985 Walker et al. Mar 2015 A1
20150079152 Wuollett et al. Mar 2015 A1
20150094674 Pratt et al. Apr 2015 A1
20150104486 Bonnefin et al. Apr 2015 A1
20150112311 Hammond et al. Apr 2015 A1
20150119831 Robinson et al. Apr 2015 A1
20150119834 Locke et al. Apr 2015 A1
20150141941 Allen et al. May 2015 A1
20150148785 Kleiner May 2015 A1
20150174304 Askem et al. Jun 2015 A1
20150245949 Locke et al. Sep 2015 A1
20150246164 Heaton et al. Sep 2015 A1
20150250979 Loske Sep 2015 A1
20150265741 Duncan et al. Sep 2015 A1
20150265743 Hanson et al. Sep 2015 A1
20150320901 Chandrashekhar-Bhat et al. Nov 2015 A1
20160008293 Shi et al. Jan 2016 A1
20160051724 Sahin et al. Feb 2016 A1
20160067107 Cotton Mar 2016 A1
20160100987 Hartwell et al. Apr 2016 A1
20160106878 Yang et al. Apr 2016 A1
20160106892 Hartwell Apr 2016 A1
20160166422 Karim et al. Jun 2016 A1
20160193244 Ota et al. Jul 2016 A1
20160222548 Agboh Aug 2016 A1
20160271178 Hauser et al. Sep 2016 A1
20160287743 Andrews Oct 2016 A1
20170049111 Patton et al. Feb 2017 A1
20170189237 Locke et al. Jul 2017 A1
20190293881 Ramjit et al. Oct 2019 A1
20190298577 Locke et al. Oct 2019 A1
20190298578 Shulman et al. Oct 2019 A1
20190298582 Addison et al. Oct 2019 A1
20190307611 Askem et al. Oct 2019 A1
20190307612 Hartwell et al. Oct 2019 A1
20190307934 Allen et al. Oct 2019 A1
20190314209 Ha et al. Oct 2019 A1
20190321509 Chakravarthy et al. Oct 2019 A1
20190321526 Robinson et al. Oct 2019 A1
20190336641 Nisbet Nov 2019 A1
20190336658 Heaton et al. Nov 2019 A1
20190336739 Locke et al. Nov 2019 A1
20190343979 Kearney et al. Nov 2019 A1
20190343993 Weston Nov 2019 A1
20190343994 Greener Nov 2019 A1
20190350763 Pratt et al. Nov 2019 A1
20190350765 Heagle et al. Nov 2019 A1
20190351111 Locke et al. Nov 2019 A1
20190358361 McInnes et al. Nov 2019 A1
20190374408 Robles et al. Dec 2019 A1
20190374673 Hoefinghoff et al. Dec 2019 A1
20190380881 Albert et al. Dec 2019 A1
20190380882 Taylor et al. Dec 2019 A1
20190380883 MacPhee et al. Dec 2019 A1
20190381222 Locke et al. Dec 2019 A9
20190388577 Chandrashekhar-Bhat et al. Dec 2019 A1
20190388579 MacPhee et al. Dec 2019 A1
20190388589 MacPhee et al. Dec 2019 A1
20200022844 Blott et al. Jan 2020 A1
20200023103 Joshi et al. Jan 2020 A1
20200030499 Menon et al. Jan 2020 A1
20200038023 Dunn Feb 2020 A1
20200038639 Patel et al. Feb 2020 A1
20200046565 Barta et al. Feb 2020 A1
20200046568 Sexton Feb 2020 A1
20200061254 Joshi et al. Feb 2020 A1
20200069835 Hissink et al. Mar 2020 A1
20200069851 Blott et al. Mar 2020 A1
20200078225 Grillitsch et al. Mar 2020 A1
20200085626 Braga et al. Mar 2020 A1
20200085630 Robinson et al. Mar 2020 A1
20200100945 Albert et al. Apr 2020 A1
20200113741 Rehbein et al. Apr 2020 A1
20200114049 Wall Apr 2020 A1
20200129675 Robinson et al. Apr 2020 A1
20200138754 Johnson May 2020 A1
20200139023 Haggstrom et al. May 2020 A1
20200146894 Long et al. May 2020 A1
20200155379 Shaw et al. May 2020 A1
20200170843 Collinson et al. Jun 2020 A1
20200171197 Hubbell et al. Jun 2020 A1
20200254139 Phillips et al. Aug 2020 A1
20200261275 Manwaring et al. Aug 2020 A1
20200276055 Randolph et al. Sep 2020 A1
20200297894 Koyama et al. Sep 2020 A1
20200299865 Bonnefin et al. Sep 2020 A1
20200306091 Lee et al. Oct 2020 A1
20200315854 Simmons et al. Oct 2020 A1
20200330283 Locke et al. Oct 2020 A1
20200330284 Locke et al. Oct 2020 A1
20200337719 Ingram et al. Oct 2020 A1
Foreign Referenced Citations (31)
Number Date Country
1307489 Aug 2001 CN
0525062 Feb 1993 EP
2000510539 Aug 2000 JP
2003510475 Mar 2003 JP
2006110393 Apr 2006 JP
2008518726 Jun 2008 JP
2008529618 Aug 2008 JP
2011504127 Feb 2011 JP
WO-9116490 Oct 1991 WO
WO-9312275 Jun 1993 WO
WO-9519795 Jul 1995 WO
WO-1998-046818 Oct 1998 WO
WO-1999-064080 Dec 1999 WO
WO-2000-001425 Jan 2000 WO
WO-2001-023653 Apr 2001 WO
2005013543 Mar 2005 WO
WO-2006052839 May 2006 WO
WO-2006087021 Aug 2006 WO
WO-2010085426 Jul 2010 WO
WO-2010122665 Oct 2010 WO
WO-2011077096 Jun 2011 WO
2011121394 Oct 2011 WO
2011135284 Nov 2011 WO
2011144888 Nov 2011 WO
2013015827 Jan 2013 WO
WO-2013079947 Jun 2013 WO
WO-2013079949 Jun 2013 WO
2013126049 Aug 2013 WO
2014014842 Jan 2014 WO
2015145117 Oct 2015 WO
2015173546 Nov 2015 WO
Non-Patent Literature Citations (35)
Entry
Australian Patent Application No. 2012343581 Examiner's Second Report dated Jun. 27, 2016.
Australian Patent Application No. 2012343583 Patent Examination Report No. 1 dated Aug. 10, 2016.
Chinese Patent Application No. 201280068356.8 First Office Action dated Jun. 8, 2015.
Chinese Patent Application No. 201280068356.8 Second Office Action dated Apr. 18, 2016.
Chinese Patent Application No. 201280068502.7 First Office Action dated Sep. 6, 2015.
Chinese Patent Application No. 201280068502.7 Second Office Action dated Jun. 15, 2016.
Colombia Patent Application No. 14-139575-8 Writ dated Jun. 1, 2016.
Columbia Patent Application No. 14-139580 Writ dated Jun. 1, 2016.
PCT/GB2012/052950 International Preliminary Report on Patentability dated Jun. 3, 2014.
PCT/GB2012/052952 International Preliminary Report on Patentability dated Jun. 3, 2014.
PCT/GB2012/052952 International Search Report dated Mar. 1, 2013.
U.S. Appl. No. 14/362,050 Office Action dated Apr. 29, 2015.
U.S. Appl. No. 14/362,050 Office Action dated Feb. 10, 2016
Karamuk, E., et al., “TISSUPOR: Development of a structured wound dressing based on a textile composite functionalised by embroidery technology,” KTI. Projekt No. 511, (2001), XP55054592, available from: URL:http://www.tissupor.com/pdf/tissupor_kti.pdf.
PCT-GB-2012-052950 International Search Report dated Feb. 28, 2013.
Australian Patent Application No. 2012343583 Examiner's First Report dated Aug. 10, 2016.
Chinese Patent Application No. 201280068356.8 Third Office Action dated Oct. 25, 2016.
Chinese Patent Application No. 201280068502.7 Third Office Action dated Feb. 4, 2017.
Colombia Patent Application No. 14-139575 Writ No. 11665 dated Oct. 19, 2016 (in Spanish) with foreign associate reporting letter dated Nov. 3, 2016 (in English).
Colombia Patent Application No. 14-139850 Writ dated Oct. 12, 2016.
European Patent Application No. 12798352.6 Communication dated Aug. 29, 2016.
Japanese Patent Application No. 2014-543971 Office Action dated Nov. 29, 2016.
Japanese Patent Application No. 2014-543972 Office Action dated Dec. 20, 2016.
New Zealand Patent Application No. 626695 Further Examination Report dated Sep. 9, 2016.
New Zealand Patent Application No. 723782 Examiner's First Report dated Sep. 9, 2016.
Chinese Patent Application No. 201280028356.8 Office Action dated May 26, 2017.
Columbia Patent Application No. 14139575 Resolution No. 28622 dated May 23, 2017.
Guha et al., Predicting yarn tenacity: A comparison of mechanistic, statistical, and neural network models. The Journal of Textile Institute, 92(Issue 2, Parts 1 and 2):4 pages, 2001. Abstract.
Ramey et al., Relationship of cotton fiber properties to yarn tenacity. Textile Research Journal, 2 pages, Jul. 2, 2016. Abstract.
Japanese Patent Application No. 2014-543971 Office Action dated Aug. 1, 2017.
Chinese Patent Application No. 201280068356.8 Office Action dated May 3, 2018.
European Patent Application No. 18162727.4 Extended European Search Report dated Aug. 6, 2018.
Japanese Opposition No. 2018-700440 Decision of Opposition to Patent dated Oct. 5, 2018.
Japanese Opposition No. 2018-700440 Notice of Opposition to Patent dated May 30, 2018.
Korean Patent Application No. 10-2014-7017863 Office Action dated Aug. 10, 2018.
Related Publications (1)
Number Date Country
20140323999 A1 Oct 2014 US